To be used simultaneously with interpretive review by pathologists, the software has been designed to detect if cancer in the breast has metastasised to the lymphatic system.
It helps to increase diagnostic accuracy and efficiency in the detection of breast cancer metastases of any size in lymph node tissue.
Using AI, Paige Breast Lymph Node allows pathologists to detect tumour metastases, including small micro-metastases.
It has a slide level sensitivity of more than 98% in detecting different size metastases.
The device will display a positive indication of metastatic breast cancer at the individual lymph node level using the company’s TissueMap.
TissueMap highlights all the regions on a slide that are suspicious for cancer.
Paige Breast Lymph Node highlights both slides and cases with suspected positive lymph nodes, which enables prioritisation and efficient review by pathologists.
Paige founder and chief medical officer David Klimstra said: “Accurate detection of breast cancer metastases is paramount for physicians and their patients, but it can be a laborious, manual task for pathologists.
“Paige Breast Lymph Node offers pathologists a quicker and more efficient way to analyse large quantities of lymph node tissue, as well as peace of mind for them and their patients.”
As part of the Paige Breast Suite, the new device will be available to customers immediately.
The company stated that the Paige Breast Lymph Node software uses the same AI technology as Paige Prostate, which has the capability to work with a range of staining techniques, data and scanning artefacts.